Patents by Inventor Jürgen Klattig

Jürgen Klattig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON
    Publication number: 20230357398
    Abstract: The present disclosure provides novel fully human antibodies and antibody fragments specific for human CD3 epsilon.
    Type: Application
    Filed: September 22, 2021
    Publication date: November 9, 2023
    Inventors: Andreas BÜLTMANN, Steffen RUNZ, Tschimegma BATAA, Markus MOOSMEIER, Nicole HAUBST, Jürgen KLATTIG, Yvonne STARK
  • ANTIBODIES FOR IL-17C
    Publication number: 20200216529
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Inventors: Jan Dominik HAAS, Jürgen KLATTIG, Nick Ernest René VANDEGHINSTE
  • Antibodies for IL-17C
    Patent number: 10633439
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 28, 2020
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Jan Dominik Haas, Jürgen Klattig, Nick Ernest Rene Vandeghinste
  • ANTIBODIES FOR IL-17C
    Publication number: 20200010542
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that bivalently bind to homodimeric IL-17C.
    Type: Application
    Filed: August 5, 2019
    Publication date: January 9, 2020
    Inventors: Jürgen Klattig, Nick Ernest René Vandeghinste, Teresa Auf Der Garcia
  • ANTIBODIES FOR IL-17C
    Publication number: 20190202906
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Application
    Filed: February 26, 2019
    Publication date: July 4, 2019
    Inventors: Jan Dominik HAAS, Jürgen Klattig, Nick Ernest Rene Vandeghinste
  • Antibodies for IL-17C
    Patent number: 10259869
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: April 16, 2019
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Jan Dominik Haas, Jürgen Klattig, Nick Ernest René Vandeghinste
  • ANTIBODIES FOR IL-17C
    Publication number: 20190048071
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Application
    Filed: February 17, 2017
    Publication date: February 14, 2019
    Applicants: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Jan Dominik HAAS, Jürgen KLATTIG, Nick Ernest René VANDEGHINSTE
  • ANTIBODIES FOR IL-17C
    Publication number: 20180340024
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Application
    Filed: August 8, 2018
    Publication date: November 29, 2018
    Inventors: Jan Dominik HAAS, Jürgen KLATTIG, Nick Ernest René VANDEGHINSTE
  • Antibodies for IL-17C
    Publication number: 20170342147
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that bivalently bind to homodimeric IL-17C.
    Type: Application
    Filed: December 15, 2015
    Publication date: November 30, 2017
    Inventors: Jürgen Klattig, Nick Ernest René Vandeghinste, Teresa Garcia
  • Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
    Patent number: 9238689
    Abstract: The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: January 19, 2016
    Assignee: Morpho Sys AG
    Inventors: Swen Zierow, Juergen Klattig
  • ANTIBODIES THAT ARE CROSS-REACTIVE FOR MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AND D-DOPACHROME TAUTOMERASE (D-DT)
    Publication number: 20140120115
    Abstract: The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof.
    Type: Application
    Filed: July 13, 2012
    Publication date: May 1, 2014
    Applicant: MorphoSys AG
    Inventors: Swen Zierow, Juergen Klattig